United States securities and exchange commission logo April 19, 2022 Billy Cho Chief Financial Officer Zai Lab Ltd 4560 Jinke Road Bldg. 1, Fourth Floor Pudong Shanghai, China Re: Zai Lab Ltd Form 10-K for Fiscal Year Ended December 31, 2021 Filed March 1, 2022 File No. 001-38205 Dear Mr. Cho: We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 10-K for Fiscal Year Ended December 31, 2021 Disclosures Relating to Our Chinese Operations, page ii 1. Please provide prominent disclosure here discussing whether your auditor is subject to the determinations announced by the PCAOB on December 16, 2021 and whether and how the Holding Foreign Companies Accountable Act (the "HFCAA") and related regulations will affect your company, including disclosing that you were identified by the Commission under the HFCAA. Also, disclose that the United States Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if enacted, would decrease the number of non-inspection years from three years to two, thus reducing the time period before your securities may be prohibited from trading or delisted. Billy Cho FirstName Zai Lab LtdLastNameBilly Cho Comapany April NameZai Lab Ltd 19, 2022 April 219, 2022 Page 2 Page FirstName LastName We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Tracie Mariner at 202-551-3744 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Please contact Jason Drory at 202-551-8342 or Jeffrey Gabor at 202-551-2544 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas Danielski